Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1579-1590

  Filosto, Simone ^a   Baston, David S ^a   Chung, Samuel ^a   Becker, Cathleen R ^a   Goldkorn, Tzipora ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CIGARETTE SMOKE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHINESE HAMSTER; CONTROLLED STUDY; DRUG CONFORMATION; IC 50; INDUCED RESISTANCE; LUNG NON SMALL CELL CANCER; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84882257259     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1029     Document Type: Article

References (52)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-22.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-smallcell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21: 3798-807.
4. Polosa R, Prosperini G, Leir SH, Holgate ST, Lackie PM, Davies DE. Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 1999;20:914-23.
5. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 1998;90:1198-205.
6. O'Donnell RA, Richter A, Ward J, Angco G, Mehta A, Rousseau K, et al. Expression of ErbB receptors and mucins in the airways of long term current smokers. Thorax 2004;59:1032-40.
7. Linggi B, Carpenter G. ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol 2006;16:649-56.
8. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
9. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
10. Mountzios G, Fouret P, Soria JC. Mechanisms of disease: Signal transduction in lung carcinogenesis-A comparison of smokers and never-smokers. Nat Clin Pract Oncol 2008;5:610-8.
11. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors-The bull's-eye hits the arrow. Cancer Cell 2004;5:411-5.
12. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010;29:23-36.
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
15. Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004;304:1458-61.
16. Weinstein IB. Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 2002;297:63-4.
17. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62.
18. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-70.
19. Mitchell P, Mok T, Barraclough H, Strizek A, Lew R, van Kooten M. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: A systematic review. Clin Lung Cancer 2012;13:239-51.
20. Filosto S, Becker CR, Goldkorn T. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther 2012;11: 795-804.
21. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A 1995;92:6981-5.
22. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 1999;96:1415-20.
23. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009;29: 5858-71.
24. Chung BM, Dimri M, George M, Reddi AL, Chen G, Band V, et al. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 2009;28:1821-32.
25. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894-906.
26. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51: 1417-23.
27. Khan EM, Lanir R, Danielson AR, Goldkorn T. EGF receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking. FASEB J 2008;22:910-7.
28. Filosto S, Khan E, Tognon E, Becker C, Ashfaq M, Ravid T, et al. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PLoS ONE 2011;6:e23240.
29. Dimri M, Naramura M, Duan L, Chen J, Ortega-Cava C, Chen G, et al. Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: C-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res 2007;67:4164-72.
30. Kim H, Chan R, Dankort DL, Zuo D, Najoukas M, Park M, et al. The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: Implications for ErbB-2 mediated signaling and transformation. Oncogene 2005;24:7599-607.
31. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-49.
32. Yang S, Park K, Turkson J, Arteaga CL. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp Cell Res 2008;314:413-9.
33. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-4.
34. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42.
35. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80.
36. Burgess DJ. Breast cancer: SRC hits the mark. Nat Rev Cancer 2011;11:314-5.
37. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-86.
38. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene 2008; 27:3596-604.
39. Rahman I. The role of oxidative stress in the pathogenesis of COPD: Implications for therapy. Treat Respir Med 2005;4:175-200.
40. Ganesan S, Unger BL, Comstock AT, Angel KA, Mancuso P, Martinez FJ, et al. Aberrantly activated EGFR contributes to enhanced IL-8 expression in COPD airways epithelial cells via regulation of nuclear FoxO3A. Thorax 2013;68:131-41.
41. Woodruff PG. Novel outcomes and end points: Biomarkers in chronic obstructive pulmonary disease clinical trials. Proc Am Thorac Soc 2011;8:350-5.
42. Sudol M. From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management. Oncogene 2011;30:3003-10.
43. Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol 2008;19:1219-23.
44. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-76.
45. Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol 2009;10:84.
46. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003; 39:1447-55.
47. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Srcmediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
48. Gotoh N, Tojo A, Hino M, Yazaki Y, Shibuya M. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem Biophys Res Commun 1992;186:768-74.
49. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, et al. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 2012;149:860-70.
50. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004;23:7918-27.
51. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906-9.
52. ShvartsmanDE, Donaldson JC, DiazB, Gutman O, MartinGS,Henis YI. Src kinase activity and SH2 domain regulate the dynamics of Src association with lipid and protein targets. J Cell Biol 2007;178: 675-86.